Background: Superior sulcus tumors are a complex subset of tumors accounting for less than 5% of lung tumors. Methods: Twenty-three patients admitted between 2001 and 2007 were included in the study,. Computed tomography scan of the chest was considered the primary diagnostic and staging investigation for all patients. Radiation therapy was given preoperatively to 20 patients, neoadjuvant chemotherapy was given to 13 patients. Results: There were 22 men and one woman in the study. The mean age was 53 years. Lobectomy was performed in 20 patients and wedge resection was done for three patients. Three to five ribs were resected in all patients. Extended resections were performed in eight patients. Positive mediastinal lymph nodes were found six patients. The staging was: Stage IIB (11 patients); Stage IIIA (four patients), Stage IIIB (six patients) and Stage IV (two patients). Negative resection margin was achieved in 18 patients. Postoperative complications developed in nine patients, there was one operation related mortality. Tumor recurrence developed in 16 patients. The mean survival time was 2.8 years and the overall 5-years survival was 26%. Conclusion: Multimodality treatment gives satisfactory results with low morbidity and mortality rates and acceptable survival.

Purpose: This is retrospective study-reviewing patients with unresectable pleural mesothelioma who received IMRT as part of their treatment course. This work aimed to study pain control and improvement among this group of patients. Methods and Materials: Between 2016 and 2020, 50 patients with unresectable malignant pleural mesothelioma following chemotherapy, of both sex and different age groups, were treated with pleural IMRT to the hemithorax (median dose, 46.8 Gy) at The National Cancer Institute, Cairo University. Results: Of the 30 patients, 38% had stage II, 62 % had stage III, and all received induction chemotherapy (mostly cisplatin and pemetrexed) before IMRT.Patients were evaluable at week 5 post radiotherapy, 17 patients (56.7%) had an improvement of ≥30 % while 6 patients (20 %) had < 30 % pain improvement and 7 patients (23.3%) reported no pain improvement, with overall response rate was 77 %. Conclusion: Treating malignant pleural mesothelioma patients with IMRT is a feasible treatment option with an acceptable rate of pneumonitis.